Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lemaitre Vascular (LMAT) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Lemaitre Vascular (LMAT) over the last 16 years, with Q3 2025 value amounting to $28.8 million.

  • Lemaitre Vascular's Cash from Operations rose 10190.93% to $28.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.3 million, marking a year-over-year increase of 8463.01%. This contributed to the annual value of $44.1 million for FY2024, which is 2006.2% up from last year.
  • As of Q3 2025, Lemaitre Vascular's Cash from Operations stood at $28.8 million, which was up 10190.93% from $20.3 million recorded in Q2 2025.
  • Lemaitre Vascular's 5-year Cash from Operations high stood at $28.8 million for Q3 2025, and its period low was $2.3 million during Q1 2023.
  • Over the past 5 years, Lemaitre Vascular's median Cash from Operations value was $9.6 million (recorded in 2024), while the average stood at $10.5 million.
  • Data for Lemaitre Vascular's Cash from Operations shows a peak YoY increase of 41084.95% (in 2021) and a maximum YoY decrease of 6427.36% (in 2021) over the last 5 years.
  • Quarter analysis of 5 years shows Lemaitre Vascular's Cash from Operations stood at $5.1 million in 2021, then decreased by 19.36% to $4.1 million in 2022, then soared by 163.58% to $10.7 million in 2023, then surged by 41.28% to $15.2 million in 2024, then surged by 89.46% to $28.8 million in 2025.
  • Its Cash from Operations stands at $28.8 million for Q3 2025, versus $20.3 million for Q2 2025 and $9.0 million for Q1 2025.